Bouguen G, Huguet A, Amiot A, et al. - Researchers conducted a retrospective study of data collected from the Groupe d’Etude Thérapeutique des Affections Inflammatoires Digestives trial, from January 1, 2000, through December 31, 2017, in order to evaluate the long-term effectiveness and safety of anti-TNF therapy for people with internal fistulas. A total of 68 people who underwent major abdominal surgery, after a median follow-up period of 3.5 years. A concentration of C-reactive protein >18 mg/L, and albumin concentration <36 g/L, the appearance of an abscess at the fistula diagnosis, the association among the appearance of a stricture independently with the necessity for surgery. Overall, from a large clinical trial, a retrospective analysis of data was observed that anti-TNF therapy delays or prevents surgery for almost half of people with CD and luminal fistulas. Perhaps the risk of sepsis-related death or gastrointestinal malignancies were increased by anti-TNF therapy.